

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5145039

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	JEFFREY PAUL STONEHOUSE	12/15/2015
RECEIVING PARTY DATA		
Name:	ASTRAZENECA UK LIMITED	
Street Address:	2 KINGDOM STREET	
City:	LONDON	
State/Country:	ENGLAND	
Postal Code:	W26BD	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16009590
CORRESPONDENCE DATA		
Fax Number:	(301)398-9306	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	3013980000	
Email:	patents@astrazeneca.com	
Correspondent Name:	ASTRAZENECA MEDIMMUNE	
Address Line 1:	ONE MEDIMMUNE WAY	
Address Line 4:	GAITHERSBURG, MARYLAND 20878	
ATTORNEY DOCKET NUMBER:	200205-US-CNT[2]	
NAME OF SUBMITTER:	KIM NOROOZI	
SIGNATURE:	/Kim Noroozi/	
DATE SIGNED:	09/18/2018	
Total Attachments: 5		
source=2015_12_15_executed Stonehouse#page1.tif		
source=2015_12_15_executed Stonehouse#page2.tif		
source=2015_12_15_executed Stonehouse#page3.tif		
source=2015_12_15_executed Stonehouse#page4.tif		
source=2015_12_15_executed Stonehouse#page5.tif		

THIS CONFIRMATORY ASSIGNMENT is made the 30th day of November 2015 (the “Effective Date”)

BY AND BETWEEN

Jeffrey, Paul STONEHOUSE a British citizen of c/o AstraZeneca Intellectual Property, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States (the “Inventor(s)”)

AND

ASTRAZENECA UK LIMITED, a company incorporated in England and Wales under No. 3674842 with registered office address at 2 Kingdom Street, London, England W2 6BD (“AstraZeneca”)

Recitals

WHEREAS

- A. The Inventor(s) have made certain inventions (the “Inventions”) in respect of which the patent application(s) specified in the attached Schedule have been filed (the “Patent Application(s)”).
- B. The Inventor(s) were at all relevant times an employee of AstraZeneca.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. In consideration of the amounts paid to the Inventor(s) pursuant to their contract of employment with AstraZeneca, the Inventor(s) hereby confirm(s) that by virtue of their employment with AstraZeneca they have assigned, and in so far as there may be any outstanding Rights that have not been assigned to AstraZeneca do hereby assign, with full title guarantee, free from all and any charges or other third party rights, to AstraZeneca absolutely all their right, title and interest in and to the Inventions, the Patent Application(s) and any Patents; any divisions, continuations and continuations-in-part of the Patent Application(s); any re-issues, re-examinations, or extensions of any and all Patents; the right to file patent applications directly in the name of AstraZeneca or an affiliated company of AstraZeneca (in countries or regions where filings are permissible); and the right to claim priority rights deriving from the Patent Application(s) (collectively, the “Rights”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Inventor(s) warrant(s) that the Rights are unencumbered. The Inventor(s) acknowledge(s) that AstraZeneca shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and the Inventor(s) waive(s) any right of first refusal that they may have for acquiring such Rights. The Inventor(s) further acknowledge(s) that insofar as and solely to the extent that the Rights apply to India, the amount paid to the Inventor(s) pursuant to their contract of employment includes nominal consideration of One GBP (£1.00).
2. The Inventor(s) each hereby agree(s) with AstraZeneca that their assignment to AstraZeneca includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Patent Application(s), including all rights to recover damages, profits and injunctive relief for infringement of any of the Patent Application(s).
3. The Inventor(s) each hereby agree(s) with AstraZeneca that they will execute such further documents and give such assistance at the expense of AstraZeneca as AstraZeneca may require:
 - a) to secure the vesting in AstraZeneca of all rights in the Patent Application(s) and in such parties to whom AstraZeneca may assign its rights in the Patent Applications;
 - b) to defeat any challenge to the validity of and resolve any questions concerning the Patent Application(s); and
 - c) to apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Patent Application(s), including the right to claim convention priority from such applications and including, without limitation, cooperating in any

proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.

4. The Inventor(s), on behalf of itself and its successors, assigns, nominees, or other legal representatives, does hereby covenant and agree with AstraZeneca that they shall, at the expense of AstraZeneca, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by AstraZeneca to enable AstraZeneca or its successors, nominees or assigns to enjoy the full benefit of the rights assigned by this agreement.

5. The Inventor(s) on behalf of itself and its successors, assigns, nominees, or other legal representatives, do hereby authorize AstraZeneca, its successors, assigns, or nominees, including its patent agents, to amend the present assignment document to insert or correct the filing date, serial number or other identifying information of the Patent Application(s) and/or Patents as may be needed to record same.

6. AstraZeneca accepts the above assignment.

7. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.


This agreement has been entered into on the Effective Date.

Signed at: CAMBRIDGE, MA, USA

Date: 15 DEC 2015



Jeffrey, Paul STONEHOUSE

Witnessed by:


Name: Satiya Watson

Signed at: Macclesfield, Cheshire, UK

Date: 06 January 2016




Signed for and on behalf of
ASTRAZENECA UK LIMITED

Name: Andrew COOK

Capacity: Authorised Signatory

Witnessed by:



Name:

TARA COONEY

THE SCHEDULE

THE PATENT APPLICATION(S)					
AstraZeneca Case No:	Application Ref:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
200205-AR-NP	A	Argentina	National	20150103913	30 November 2015
200205-BO-NP	B	Bolivia	National	SP-274-2015	30 November 2015
200205-ET-NP	C	Ethiopia	National	ET/P/15/313	30 November 2015
200205-GC-GCP	D	GCC	National	30489	29 November 2015
200205-WO-PCT	E	International	PCT	PCT/EP2015/077998	30 November 2015
200205-LB-NP	F	Lebanon	National	10803	01 December 2015
200205-PY-NP	G	Paraguay	National	1-[2-(AMINOMETHYL)BENZYL]-2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE	To be Advised
200205-PK-NP	H	Pakistan	National	766/2015	27 November 2015
200205-TW-NP	I	Taiwan	National	104139983	30 November 2015
200205-UY-NP	J	Uruguay	National	36.416	30 November 2015
200205-US-NP	K	USA	National	14/951979	25 November 2015
200205-VE-NP	L	Venezuela	National	000979-2015	30 November 2015
200205-BS-NP	M*	Bahamas	National	1-[2-(AMINOMETHYL)BENZYL]-2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE	To be Advised
200205-JM-NP	N*	Jamaica	National	18/1/5713	30 November 2015

Patent Application(s) referenced A to L inclusive claim priority from the following US Provisional Application(s)

Application No.	Filing Date
62/085722	01 December 2014
62/166808	27 May 2015

Patent Application(s) referenced M* and N* do not claim priority